281 related articles for article (PubMed ID: 6202772)
1. Effects of deoxycoformycin in mice. II. Differences between the drug sensitivities and purine metabolizing enzymes of transplantable lymphomas of varying immunologic phenotypes.
Ratech H; Kim J; Asofsky R; Thorbecke GJ; Hirschhorn R
J Immunol; 1984 Jun; 132(6):3077-84. PubMed ID: 6202772
[TBL] [Abstract][Full Text] [Related]
2. Specific immunosuppressive effects of constant infusion of 2'-deoxycoformycin.
Trotta PP; Tedde A; Ikehara S; Pahwa R; Good RA; Balis ME
Cancer Res; 1981 Jun; 41(6):2189-96. PubMed ID: 6972248
[TBL] [Abstract][Full Text] [Related]
3. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
Yu AL; Bakay B; Kung FH; Nyhan WL
Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
[TBL] [Abstract][Full Text] [Related]
4. Toxicity and immunosuppressive activity of binary combinations of 2'-deoxycoformycin and 2'-deoxyadenosine.
Paine RM; Weston BJ; Clink HM; Kohn J; Neville AM; McGhee KG; Harrap KR
Cancer Treat Rep; 1981; 65(3-4):259-66. PubMed ID: 6972254
[TBL] [Abstract][Full Text] [Related]
5. 2'Deoxycoformycin and deoxyadenosine affect IL 2 production and IL 2 receptor expression of human T cells.
Ruers TJ; Buurman WA; van der Linden CJ
J Immunol; 1987 Jan; 138(1):116-22. PubMed ID: 3097141
[TBL] [Abstract][Full Text] [Related]
6. Specificity of 2'-deoxycoformycin inhibition of adenosine metabolism in intact human skin fibroblasts.
Holland MJ
Res Commun Chem Pathol Pharmacol; 1986 Mar; 51(3):311-24. PubMed ID: 3486439
[TBL] [Abstract][Full Text] [Related]
7. Morphologic changes and immunohistochemical localization of adenosine deaminase in tissues of rats given injections of 2'-deoxycoformycin.
Checkik BE; Perets A; SenGupta S; Fernandes B
J Natl Cancer Inst; 1983 Nov; 71(5):999-1010. PubMed ID: 6358608
[TBL] [Abstract][Full Text] [Related]
8. Effects of deoxycoformycin in mice. III. A murine model reproducing multi-system pathology of human adenosine deaminase deficiency.
Ratech H; Hirschhorn R; Thorbecke GJ
Am J Pathol; 1985 Apr; 119(1):65-72. PubMed ID: 3872599
[TBL] [Abstract][Full Text] [Related]
9. Effects of deoxycoformycin in mice. I. Suppression and enhancement of in vivo antibody responses to thymus-dependent and -independent antigens.
Ratech H; Bell MK; Hirschhorn R; Thorbecke GJ
J Immunol; 1984 Jun; 132(6):3071-6. PubMed ID: 6609968
[TBL] [Abstract][Full Text] [Related]
10. Opposite effects of recombinant interferon-alpha A and deoxycoformycin on adenosine deaminase activity in the Daudi B lymphoblastoid cell line.
Faltynek CR
Blood; 1988 Jan; 71(1):59-64. PubMed ID: 3257147
[TBL] [Abstract][Full Text] [Related]
11. Human B lymphocytes and thymocytes but not peripheral blood mononuclear cells accumulate high dATP levels in conditions simulating ADA deficiency.
Goday A; Simmonds HA; Morris GS; Fairbanks LD
Biochem Pharmacol; 1985 Oct; 34(19):3561-9. PubMed ID: 3876835
[TBL] [Abstract][Full Text] [Related]
12. Lack of adenosine deaminase activity in cultured murine cytotoxic T lymphocytes.
Minkowski MD; Castellazzi M; Buttin G
J Immunol; 1984 Jul; 133(1):52-8. PubMed ID: 6609994
[TBL] [Abstract][Full Text] [Related]
13. Effects of deoxyadenosine on the activation of ADA inhibited T & B cells.
Webster AD; Ip H; Pereira S
Clin Exp Immunol; 1982 Dec; 50(3):587-95. PubMed ID: 6299634
[TBL] [Abstract][Full Text] [Related]
14. Enzyme activities of leukemic cells and biochemical changes induced by deoxycoformycin in vitro--lack of correlation with clinical response.
Ho AD; Ganeshaguru K; Knauf W; Dietz G; Trede I; Hoffbrand AV; Hunstein W
Leuk Res; 1989; 13(4):269-78. PubMed ID: 2785618
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas.
Kuroki Y; Shimoyama M; Inaba S; Hirose M
Jpn J Cancer Res; 1989 May; 80(5):482-9. PubMed ID: 2502523
[TBL] [Abstract][Full Text] [Related]
16. Isolation of deoxycoformycin-resistant cells with increased levels of adenosine deaminase.
Hoffee PA; Hunt SW; Chiang J
Somatic Cell Genet; 1982 Jul; 8(4):465-77. PubMed ID: 6981855
[TBL] [Abstract][Full Text] [Related]
17. 2'-Deoxycoformycin inhibition of adenosine deaminase in rat brain: in vivo and in vitro analysis of specificity, potency, and enzyme recovery.
Padua R; Geiger JD; Dambock S; Nagy JI
J Neurochem; 1990 Apr; 54(4):1169-78. PubMed ID: 2179470
[TBL] [Abstract][Full Text] [Related]
18. Animal model for immune dysfunction associated with adenosine deaminase deficiency.
Tedde A; Balis ME; Ikehara S; Pahwa R; Good RA; Trotta PP
Proc Natl Acad Sci U S A; 1980 Aug; 77(8):4899-903. PubMed ID: 6968908
[TBL] [Abstract][Full Text] [Related]
19. Metabolic abnormalities of human adenosine deaminase deficiency reproduced in the mouse by 2'-deoxycoformycin, and adenosine deaminase inhibitor.
Ratech H; Thorbecke GJ; Hirschhorn R
Clin Immunol Immunopathol; 1981 Oct; 21(1):119-27. PubMed ID: 6268339
[No Abstract] [Full Text] [Related]
20. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase.
Lee N; Russell N; Ganeshaguru K; Jackson BF; Piga A; Prentice HG; Foa R; Hoffbrand AV
Br J Haematol; 1984 Jan; 56(1):107-19. PubMed ID: 6231047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
